News

FDA slams Soon-Shiong, ImmunityBio for 'misleading' drug claims

Regulatory 72/100
July 28, 2026↗ source

The FDA issued a warning letter to ImmunityBio and founder Patrick Soon-Shiong for making false and misleading claims regarding their cancer therapy, Anktiva. The agency criticized the company for suggesting the drug treats 'all cancers' without evidence, failing to disclose required combination use with a vaccine, and downplaying serious risks. The FDA also challenged claims that the treatment renders patients 'cancer free,' stating that such assertions are not supported by clinical data.

Related peptides

Every claim on this page is sourced. Reliability scores are tier-capped and server-normalized (0–100; green ≥70, amber ≥40, red <40). Drill through to the source page to verify.